Caresyntax
Caresyntax, founded by Dennis Kogan and Bjoern von Siemens, is a surgical intelligence platform that transforms operating room data into actionable insights.
Profile
They provide a digital surgery platform that uses AI to analyze OR data for real-time insights and improved surgical outcomes.
Caresyntax, founded by Dennis Kogan and Bjoern von Siemens, is a surgical intelligence platform that transforms operating room data into actionable insights. Headquartered in San Francisco and Berlin, the company has expanded to over 4,200 operating rooms globally, supporting more than three million procedures annually. In July 2025, Matt Krueger was appointed CEO, succeeding the founders, who remain on the board.
Caresyntax's platform integrates surgical devices, video streams, and EMR data to optimize OR workflows and improve patient outcomes. The company has consistently delivered over 50% organic revenue growth, backed by a $130 million Series C funding round in 2021, led by PFM Health Sciences and joined by BlackRock and ProAssurance. Caresyntax was recognized in TIME's 2025 list of top healthtech companies for its AI-driven surgical analytics.
Who buys this
- Hospitals and health systems seeking to optimize OR performance
- Surgeons and surgical teams aiming to reduce variability in outcomes
- Medical malpractice insurers like Relyens and ProAssurance for risk mitigation
- Medical device and pharmaceutical companies leveraging real-world evidence
- Academic institutions and training programs for surgical education
Strengths and what to watch
Strengths
- Proven adoption in over 4,200 operating rooms globally, indicating strong market penetration
- Partnerships with major insurers and health systems validate its risk-reduction claims
- Consistent 50%+ organic revenue growth demonstrates scalable business model
Watch for
- Leadership transition in 2025 with new CEO replacing founders, potentially altering strategic direction
- Dependence on value-based care adoption, which faces regulatory and reimbursement uncertainties
- High competition in surgical AI from both startups and established medtech firms
Recent moves
Key Information
- Founded
- 2013
- Headquarters
- San Francisco and Berlin
Frequently Asked Questions
What is Caresyntax and what do they do?
Caresyntax provides an AI-powered surgical intelligence platform that analyzes operating room data in real-time. Their system integrates surgical devices, video feeds, and EMR data to optimize workflows and improve patient outcomes. Used in 4,200+ ORs globally, it supports over 3 million procedures annually.
How does Caresyntax's platform help surgeons?
The platform reduces surgical variability by providing real-time analytics on OR workflows. It aggregates data from devices, video streams, and patient records to identify optimization opportunities. Surgeons receive actionable insights to improve decision-making during procedures, leading to better outcomes and reduced complications.
Who are Caresyntax's main customers?
Primary customers include hospitals optimizing OR performance, surgeons reducing outcome variability, and insurers mitigating malpractice risks. The platform also serves medical device firms needing real-world evidence and academic institutions for surgical training. Over 4,200 operating rooms globally use their technology.
What recognition has Caresyntax received?
Caresyntax was named in TIME's 2025 top healthtech companies list for its surgical AI innovations. The company has demonstrated 50%+ organic revenue growth and secured $130M Series C funding from investors including BlackRock and ProAssurance, validating its market position.
Who leads Caresyntax in 2025?
Matt Krueger became CEO in July 2025, succeeding founders Dennis Kogan and Bjoern von Siemens who remain board members. This leadership transition follows the company's global expansion to 4,200+ ORs and consistent revenue growth under the original management team.
How does Caresyntax compare to other surgical AI platforms?
Caresyntax distinguishes itself through extensive real-world adoption (4,200+ ORs), partnerships with major insurers, and integrated OR data analysis. Its consistent 50%+ growth and $130M funding round indicate strong market validation compared to newer entrants lacking comparable scale or clinical evidence.
Sources
- www.prnewswire.com — CEO transition and operational metrics
- www.prnewswire.com — Series C funding and investor details
- time.com — Inclusion in TIME's 2025 healthtech list
- caresyntax.com — Product offerings and customer benefits